A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinoma

被引：0
|
作者：
Ruffolo, Luis I.
Byrne, Matthew
Hilty, Bailey
Belt, Brian A.
Dave, Yatee
Burchard, Paul
Fisher, Terrence
Evans, Elizabeth E.
Mallow, Crystal
Boise, Megan
Carpizo, Darren
Yeh, Jen Jen
Linehan, David C.
Mulkerin, Daniel
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PANCREATIC24-A004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A004
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase 1b/2 trial of PXS-5505 combined with first line atezolizumab plus bevacizumab for treating patients with unresectable or metastatic hepatocellular carcinoma
    Burchard, Paul R.
    Ruffolo, Luis I.
    Ullman, Nicholas
    Dave, Yatee
    Belt, Brian A.
    Linehan, David C.
    Hernandez-Alejandro, Roberto
    Badri, Nabeel
    CLINICAL CANCER RESEARCH, 2022, 28 (17)
  • [32] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
    Marion Thibaudin
    Jean-David Fumet
    Benoist Chibaudel
    Jaafar Bennouna
    Christophe Borg
    Jerome Martin-Babau
    Romain Cohen
    Marianne Fonck
    Julien Taieb
    Emeric Limagne
    Julie Blanc
    Elise Ballot
    Léa Hampe
    Marjorie Bon
    Susy Daumoine
    Morgane Peroz
    Hugo Mananet
    Valentin Derangère
    Romain Boidot
    Henri-Alexandre Michaud
    Caroline Laheurte
    Olivier Adotevi
    Aurélie Bertaut
    Caroline Truntzer
    François Ghiringhelli
    Nature Medicine, 2023, 29 : 2087 - 2098
  • [33] Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial
    Zhang, Danmei
    Westphalen, C. Benedikt
    Quante, Michael
    Waldschmidt, Dirk T.
    Held, Swantje
    Kuetting, Fabian
    Dorman, Klara
    Heinrich, Kathrin
    Weiss, Lena
    Boukovala, Myrto
    Haas, Michael
    Boeck, Stefan
    Heinemann, Volker
    Probst, Victoria
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [34] Phase II trial of high-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W
    Kornek, G
    Ulrich-Pur, H
    Raderer, M
    Fiebiger, W
    Zickero, G
    Pidlich, J
    Greul, R
    Schneeweiss, B
    Depisch, D
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S147 - S147
  • [35] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, George P.
    Oberg, Ann L.
    Foster, Nathan R.
    Sargent, Daniel J.
    Jaslowski, Anthony
    Campbell, Deborah
    Hedrick, Eric
    Grothey, Axel F.
    Alberts, Steve R.
    ANNALS OF ONCOLOGY, 2006, 17 : 310 - 310
  • [36] A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
    Ulrich-Pur, H
    Kornek, GV
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Greul, R
    Schneeweiss, B
    Krauss, G
    Funovics, J
    Scheithauer, W
    CANCER, 2000, 88 (11) : 2505 - 2511
  • [37] Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
    Jia, Ru
    Si, Hai-Yan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Wang, Yanrong
    Fan, Meng-Jiao
    Miao, Meng-Meng
    Zhang, Bei
    Tong, Shuang
    Dai, Guang-Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 671 - 671
  • [38] Phase 1b trial of the MNK1/2 inhibitor tomivosertib combined with paclitaxel in patients with metastatic breast cancer.
    Ferrario, Cristiano
    Mackey, John
    Gelmon, Karen
    Sorensen, Poul H. B.
    Oo, Htoo Zarni
    Morin, Gregg B.
    del Rincon, Sonia
    Amiri, Mehdi
    Patel, Premal
    Smith, Harvey W.
    Sonenberg, Nahum
    Pollak, Michael N.
    CANCER RESEARCH, 2022, 82 (12)
  • [39] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
    Lim, Kian-Haut
    Hidalgo, Manuel
    O'Hara, Mark H.
    Spencer, Kristen R.
    Garrido-Laguna, Ignacio
    DeNardo, David G.
    Bhambhani, Vijeta
    Patrick, Gloria
    Cheng, Yaofeng
    Coma, Silvia
    Pachter, Jonathan A.
    Denis, Louis J.
    CANCER RESEARCH, 2024, 84 (02)
  • [40] Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced non-small cell lung cancer patients
    Shafique, Michael
    Fisher, Terrence
    Evans, Elizabeth
    Leonard, John
    Pastore, Desa Rae
    Mallow, Crystal
    Smith, Ernest
    Schroeder, Andreas
    Chin, Kevin
    Beck, Joseph
    Baumgart, Megan
    Govindan, Ramaswany
    Gabrail, Nashat
    Goldman, Jonathan
    Sanborn, Rachel
    Spira, Alexander
    Seetharamu, Nagashree
    Lou, Yanyan
    Mansfield, Aaron
    Zauderer, Maurice
    Fisher, Terrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345